We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cancer-Causing Agent in Cigarette Smoke Blocks Key Protein in Cells

By LabMedica International staff writers
Posted on 17 Apr 2012
Researchers have uncovered new evidence of a cancer-causing agent present in the gaseous phase of cigarette smoke that inhibits Na,K-ATPase, the sodium-potassium pump essential for the healthy, physiological functioning of cells.

Cigarette smoke (CS) has more than 4,000 components, many of which are linked to the development and progression of lung cancer. More...
Evidence has shown secondhand smoke to be almost as dangerous as primary smoke due to its impact on the cells of the body.

By studying lung cell cultures exposed to CS, the investigators identified a cancer-causing agent called reactive oxygen species (ROS) present in the gaseous phase of CS that disrupts normal cell function. Exposure to the secondhand smoke produced by as little as two cigarettes was found to almost completely inhibit Na,K-ATPase activity within a few hours.

They further examined whether Na,K-ATPase expression correlated with increasing grades of lung adenocarcinoma and survival of patients with smoking history. Immunohistochemical analysis of lung adenocarcinoma tissues revealed reduced Na,K-ATPase expression with increasing tumor grade. Using tissue microarray containing lung adenocarcinomas of patients with known smoking status, high expression of Na,K-ATPase was found to be correlated with better survival.

Overall, reduced competence of the cell's ability to regulate sodium-potassium levels was predictive of cell damage, disease progression and, ultimately, survival. For the first time, CS is shown to be associated with loss of Na,K-ATPase function and expression in lung carcinogenesis, and likely also contributes to disease progression.

"This is critical information with regard to secondhand smoke. [...] Exposure to the gaseous substance alone, which you breathe while standing near a smoker, is sufficient to cause harm," said A. K. Rajasekaran, PhD, lead scientist of the study and Director of the Nemours Center for Childhood Cancer Research (Nemours; Wilmington, DE, USA).

Dr. Lee Goodglick, Associate Professor in the Department of Pathology and Laboratory Medicine, University of California at Los Angeles (UCLA; Los Angeles, CA, USA) and cosenior author of the study, noted, "Few reliable lung cancer biomarkers that could predict survival, treatment options or response to therapy exist today. Even fewer have been recognized where the function of the biomarker is known, yielding important information about the mechanism of action. This study really accomplishes both."

This research, reported online ahead of print February 17, 2012, in the American Journal of Physiology - Lung Cell and Molecular Physiology,is the latest finding in the compendium of evidence that supports protection, especially for children, from exposure to cigarette smoke, and reveals that secondhand smoke may be even more dangerous than previously thought.

Related Links:
Nemours Center for Childhood Cancer Research
University of California at Los Angeles



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.